vivimusta

(bendamustine hydrochloride injection)

A 20-minute infusion of bendamustine indicated for adults chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) patients

VIVIMUSTA™ is an alkylating drug indicated for treatment of patients with:

IMPORTANT SAFETY INFORMATION

Contraindications: History of a hypersensitivity reaction to bendamustine, polyethylene glycol 400, dehydrated alcohol, or monothioglycerol

Myelosuppression: Delay or reduce dose, and restart treatment based on ANC and platelet count recovery [See Warnings and Precautions (Section 5.1)].

Infections: Monitor for fever and other signs of infection or reactivation of infections and treat promptly [See Warnings and Precautions (Section 5.2)].

Progressive multifocal leukoencephalopathy (PML): Monitor for new or worsening neurological, cognitive or behavioral signs or symptoms suggestive of PML [See Warnings and Precautions (Section 5.3)].

Anaphylaxis and Infusion-Related Reactions: Severe anaphylactic reactions have occurred. Monitor clinically and discontinue drug for severe reactions. Pre-medicate in subsequent cycles for milder reactions [See Warnings and Precautions (Section 5.4)].

Tumor Lysis Syndrome: May lead to acute renal failure and death; anticipate and use supportive measures in patients at high risk [See Warnings and Precautions (Section 5.5)].

Skin Reactions: Discontinue for severe skin reactions. Cases of SJS, DRESS and TEN, some fatal, have been reported [See Warnings and Precautions (Section 5.6)].

Hepatotoxicity: Monitor liver chemistry tests prior to and during treatment [See Warnings and Precautions (Section 5.7)].

Other Malignancies: Pre-malignant and malignant diseases have been reported [See Warnings and Precautions (Section 5.8)].

Extravasation Injury: Take precautions to avoid extravasation, including monitoring intravenous infusion site during and after administration [See Warnings and Precautions (Section 5.9)].

Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential and males with female partners of reproductive potential of the potential risk to a fetus and to use an effective method of contraception [See Warnings and Precautions (Section 5.10, Section 8.1)].

Adverse Reactions: Adverse reactions (> 5%) during infusion and within 24 hours post-infusion are nausea, and fatigue. Most common adverse reactions (≥15%) for CLL are anemia, thrombocytopenia, neutropenia, lymphopenia, leukopenia, hyperbilirubinemia, pyrexia, nausea, vomiting.

TO REPORT ADVERSE REACTIONS, contact Slayback Pharma LLC at 1-844-566-2505 or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.

VIV-1207-25 December 2022

Key VIVIMUSTA™ Attributes

stop-watch-icon
20-minute infusion
bottle-icon
No reconstitution required
direction-icon
Dilution required: 2 diluent options

0.9% sodium chloride injection USP or 2.5% dextrose/0.45% sodium chloride injection USP

drip-icon
250 ml admixture
temp-icon
Once diluted, final admixture is stable for or 24 hours when refrigerated

(2C˚ to 8C˚ or 36F˚ to 46F˚) OR 3 hours when stored at room temperature (15C˚ to 30C˚ or 59F˚ to 86F˚) and room light

FOR CLL1

20min-img

Days
1&2

calendar-img

up to

sync-img

Recommended VIVIMUSTA™ dosage is 100 mg/m2 administered intravenously

FOR NHL1

20min-img

Days
1&2

calendar-img

up to

sync-img

Recommended VIVIMUSTA™ dosage is 120 mg/m2 administered intravenously

1 Please refer to the VIVIMUSTA™ Prescribing Information for full dosing, dosing adjustments, preparation, administration, and storage information.

VIVIMUSTA™ Product Codes

vivimusta-product

Vial not pictured to actual size

NDC

71225-0120-01

J CODE

J9999 Not otherwise classified, antineoplastic drugs

CPT CODE

96413 Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug

Ordering Information

VIVIMUSTA™ is available at major wholesalers and specialty pharmacies:

Patient access and reimbursement services are available to qualifying VIVIMUSTA™ patients.

For more information, visit www.CONNECTdocsign.com or call 1.844.4SBCNCT (1.844.472.2628)

Timings: Monday through Friday (8 am to 6 pm) ET

VIVIMUSTA™ is an alkylating drug indicated for treatment of patients with:

IMPORTANT SAFETY INFORMATION

Contraindications: History of a hypersensitivity reaction to bendamustine, polyethylene glycol 400, dehydrated alcohol, or monothioglycerol

Myelosuppression: Delay or reduce dose, and restart treatment based on ANC and platelet count recovery [See Warnings and Precautions (Section 5.1)].

Infections: Monitor for fever and other signs of infection or reactivation of infections and treat promptly [See Warnings and Precautions (Section 5.2)].

Progressive multifocal leukoencephalopathy (PML): Monitor for new or worsening neurological, cognitive or behavioral signs or symptoms suggestive of PML [See Warnings and Precautions (Section 5.3)].

Anaphylaxis and Infusion-Related Reactions: Severe anaphylactic reactions have occurred. Monitor clinically and discontinue drug for severe reactions. Pre-medicate in subsequent cycles for milder reactions [See Warnings and Precautions (Section 5.4)].

Tumor Lysis Syndrome: May lead to acute renal failure and death; anticipate and use supportive measures in patients at high risk [See Warnings and Precautions (Section 5.5)].

Skin Reactions: Discontinue for severe skin reactions. Cases of SJS, DRESS and TEN, some fatal, have been reported [See Warnings and Precautions (Section 5.6)].

Hepatotoxicity: Monitor liver chemistry tests prior to and during treatment [See Warnings and Precautions (Section 5.7)].

Other Malignancies: Pre-malignant and malignant diseases have been reported [See Warnings and Precautions (Section 5.8)].

Extravasation Injury: Take precautions to avoid extravasation, including monitoring intravenous infusion site during and after administration [See Warnings and Precautions (Section 5.9)].

Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential and males with female partners of reproductive potential of the potential risk to a fetus and to use an effective method of contraception [See Warnings and Precautions (Section 5.10, Section 8.1)].

Adverse Reactions: Adverse reactions (> 5%) during infusion and within 24 hours post-infusion are nausea, and fatigue. Most common adverse reactions (≥15%) for CLL are anemia, thrombocytopenia, neutropenia, lymphopenia, leukopenia, hyperbilirubinemia, pyrexia, nausea, vomiting.

TO REPORT ADVERSE REACTIONS, contact Slayback Pharma LLC at 1-844-566-2505 or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.

VIV-1207-25 December 2022

The site you're about to enter is intended for US healthcare professionals only.

Please confirm that you are a US healthcare professional.